1. Home
  2. NXPL vs LEXX Comparison

NXPL vs LEXX Comparison

Compare NXPL & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextPlat Corp

NXPL

NextPlat Corp

HOLD

Current Price

$5.95

Market Cap

16.3M

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.57

Market Cap

16.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXPL
LEXX
Founded
1997
2004
Country
United States
Canada
Employees
130
7
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.3M
16.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NXPL
LEXX
Price
$5.95
$0.57
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
19.1K
64.3K
Earning Date
05-15-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$0.46
52 Week High
$8.37
$1.55

Technical Indicators

Market Signals
Indicator
NXPL
LEXX
Relative Strength Index (RSI) 43.64 47.84
Support Level $5.44 $0.56
Resistance Level $7.28 $0.70
Average True Range (ATR) 0.56 0.06
MACD -0.11 0.00
Stochastic Oscillator 8.63 33.61

Price Performance

Historical Comparison
NXPL
LEXX

About NXPL NextPlat Corp

NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: